PressMay 29, 2024 Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
PressMay 24, 2024 Reunion Neuroscience Announces Publication of Results from Early Preclinical Studies Demonstrating the Potential of Re104 for Development in Depressive Disorders
PressMay 23, 2024 atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
PressMay 23, 2024 Pharmadrug’s Securedose Announces LOI with Canadian Controlled Drug Substance Licensed Dealer for Patent Pending Pharmaceutical Grade Cocaine
PressMay 23, 2024 PharmAla CEO Nick Kadysh Pens Op-ed: Mental Health in Crisis, MDMA May Be the Prescription
PressMay 22, 2024 Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
PressMay 21, 2024 Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services
PressMay 21, 2024 Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention
PressMay 15, 2024 Filament Health Announces First Quarter 2024 Financial Results and Operational Highlights
PressMay 15, 2024 atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
PressMay 15, 2024 PharmaDrug’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
PressMay 14, 2024 Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
PressMay 14, 2024 Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
PressMay 13, 2024 PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through Development into Commercialization
PressMay 13, 2024 AbbVie (ABBV) and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
PressMay 10, 2024 Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product
PressMay 9, 2024 New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
